Cardiac allograft vasculopathy prevention: Difference between revisions
| Line 9: | Line 9: | ||
===Optimization of Immunosuppressive Therapy=== | ===Optimization of Immunosuppressive Therapy=== | ||
Options for immunosuppressive therapy for prevention of CAV include: | Options for immunosuppressive therapy for prevention of CAV include <ref name="pmid16686747">{{cite journal| author=Mehra MR| title=Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. | journal=Am J Transplant | year= 2006 | volume= 6 | issue= 6 | pages= 1248-56 | pmid=16686747 | doi=10.1111/j.1600-6143.2006.01314.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16686747 }} </ref>: | ||
* [[Immunosuppressive drugs#Drugs Acting on Immunophilins|Calcineurin inhibitors]], such as | * [[Immunosuppressive drugs#Drugs Acting on Immunophilins|Calcineurin inhibitors]], such as | ||
** [[Cyclosporine]] | ** [[Cyclosporine]] | ||
Revision as of 19:38, 1 October 2014
|
Cardiac allograft vasculopathy Microchapters |
|
Differentiating Cardiac allograft vasculopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cardiac allograft vasculopathy prevention On the Web |
|
American Roentgen Ray Society Images of Cardiac allograft vasculopathy prevention |
|
Directions to Hospitals Treating Cardiac allograft vasculopathy |
|
Risk calculators and risk factors for Cardiac allograft vasculopathy prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]
Overview
Prevention
As the pathogenesis of CAV consists of both immunological and non-immunological insults, preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy.
Optimization of Immunosuppressive Therapy
Options for immunosuppressive therapy for prevention of CAV include [1]:
- Calcineurin inhibitors, such as
- Sirolimus (Rapamycin)
- Everolimus, a Rapamycin derivative
- Corticosteroids
- Azathioprine
- Mycophenolate mofetil
Calcineurin inhibitors
References
- ↑ Mehra MR (2006). "Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy". Am J Transplant. 6 (6): 1248–56. doi:10.1111/j.1600-6143.2006.01314.x. PMID 16686747.